Unsafe injections remain a problem in the United States and throughout the world, according to a recent Centers for Disease Control and Prevention’s (CDC) Morbidity and Mortality Weekly Report.
Unsafe injections remain a problem in the United States and throughout the world, according to a recent Centers for Disease Control and Prevention’s (CDC) Morbidity and Mortality Weekly Report.
While injection safety had been a public health issue mainly in low-income and middle-income country settings, overall incidents have increased substantially in recent years. Since 2001, at least 49 outbreaks have occurred because of contamination of injectable medical products, according to the CDC. Globally, the burden of disease from unsafe injections in 2000 included approximately 20 million new hepatitis B virus infections, 2 million new hepatitis C infections, and 250,000 new HIV infections.
The CDC believes proposed engineering solutions may help prevent syringe reuse in the future. Proposals include the redesign of syringes to change color after use or the incorporation of tamper-evident packaging.
In addition, CDC and its partners in the Safe Injection Practices Coalition have developed the One & Only campaign. “The ultimate goal of the campaign is to prevent outbreaks, infections, and the need for patient notification,” the CDC stated. “Recognizing that education is necessary but not always sufficient, policies and mechanisms must be in place to support and ensure that injection safety and infection control procedures are followed [and] to mandate corrective action,” the agency added.
As part of increased patient involvement in medical decision-making, The One & Only campaign encourages patients to ask their healthcare provider about bloodborne pathogen safety.
The CDC has implemented the 4 “Es” to help prevent unsafe injection practices. They include epidemiologic surveillance, reporting, monitoring, and investigation of outbreaks potentially related to unsafe injections; educational initiatives to promote understanding and use of safe injection and basic infection control practices; enforcement and oversight by federal and state authorities; and engineering of devices, equipment, and processes to reduce or eliminate disease transmission risks.
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
March 6th 2025Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 mg dose in August 2024 for the emergency treatment of anaphylaxis in children and adults weighing at least 66 lbs.
Read More